文献速递临床试验与 GCP医学人工智能与信息学真实世界研究与卫生经济

人工智能与人工教练在糖尿病预防中的有效性:随机对照试验研究方案

Effectiveness of artificial intelligence vs. human coaching in diabetes prevention: a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-05-16

本研究为开放标签、多中心、非劣效性随机对照试验,计划纳入368例超重或肥胖的糖尿病前期成人,比较全自动人工智能驱动的数字糖尿病预防计划(ai-DPP)与基于人工教练的标准糖尿病预防计划(h-DPP)的有效性。主要终点为12个月时达到美国疾病控制与预防中心(CDC)的2型糖尿病风险降低基准,次要终点包括6个月和12个月时糖化血红蛋白、体重、体力活动、项目参与度和成本效果的变化。

要点

  • 研究比较全自动AI驱动数字DPP与人工教练DPP在糖尿病前期成人中的有效性。
  • 主要终点为12个月时达到CDC的2型糖尿病风险降低基准。
  • 计划纳入368例体重指数升高且实验室确诊糖尿病前期的成人。

核心结论

  • 该试验将直接比较全自动人工智能驱动的数字糖尿病预防计划与基于人工教练的标准糖尿病预防计划的有效性。
  • 若被证明有效,全自动AI驱动的数字DPP可能成为可扩展且具成本效益的策略。

研究设计与样本

  • 开放标签、多中心、非劣效性随机对照试验。
  • 计划纳入368例体重指数升高且实验室确诊糖尿病前期的成人,等比例随机分配至ai-DPP组或h-DPP组。
  • ai-DPP组使用智能手机应用和蓝牙体重秤,h-DPP组转诊至CDC认可的糖尿病预防计划。
  • 研究对象为18至75岁、实验室确诊糖尿病前期、体重指数≥25 kg/m2(亚洲人≥23 kg/m2)、具备英语能力且使用智能手机的成人。
  • 研究在美国巴尔的摩的约翰斯·霍普金斯医学中心和宾夕法尼亚州雷丁的Reading Hospital(Tower Health)开展。

主要发现

  • 主要终点为12个月时达到CDC的2型糖尿病风险降低基准,定义为以下任一:至少5%体重下降;至少4%体重下降且平均每周至少150分钟体力活动;或糖化血红蛋白至少降低0.2个百分点。
  • 体力活动将在基线和整个试验期间以1个月为间隔通过连续活动记录仪客观测量。
  • 次要终点在6个月和12个月评估,包括糖化血红蛋白、体重、体力活动指标、项目参与度和成本效果的变化。

关键数值与推荐

  • CDC的2型糖尿病风险降低基准定义为至少5%体重下降、或至少4%体重下降且平均每周至少150分钟体力活动、或糖化血红蛋白至少降低0.2个百分点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prediabetes is a highly prevalent condition that heralds an increased risk of progression to type 2 diabetes, along with associated microvascular and macrovascular complications. The Diabetes Prevention Program (DPP) is an established effective intervention for diabetes prevention. However, participation in this 12-month lifestyle change program has historically been low. Digital DPPs have emerged as a scalable alternative, accessible asynchronously and recognized by the Centers for Disease Control and Prevention (CDC). Yet, most digital programs still incorporate human coaching, potentially limiting scalability. Furthermore, existing effectiveness results of digital DPPs are primarily derived from per protocol, longitudinal non-randomized studies, or comparisons to control groups that do not represent the standard of care DPP. The potential of an AI-powered DPP as an alternative to the DPP is yet to be investigated. We propose a randomized controlled trial (RCT) to directly compare these two approaches. METHODS: This open-label, multicenter, non-inferiority RCT will compare the effectiveness of a fully automated AI-powered digital DPP (ai-DPP) with a standard of care human coach-based DPP (h-DPP). A total of 368 participants with elevated body mass index (BMI) and prediabetes will be randomized equally to the ai-DPP (smartphone app and Bluetooth-enabled body weight scale) or h-DPP (referral to a CDC recognized DPP). The primary endpoint, assessed at 12 months, is the achievement of the CDC's benchmark for type 2 diabetes risk reduction, defined as any of the following: at least 5% weight loss, at least 4% weight loss and at least 150 min per week on average of physical activity, or at least a 0.2-point reduction in hemoglobin A1C. Physical activity will be objectively measured using serial actigraphy at baseline and at 1-month intervals throughout the trial. Secondary endpoints, evaluated at 6 and 12 months, will include changes in A1C, weight, physical activity measures, program engagement, and cost-effectiveness. Participants include adults aged 18-75 years with laboratory confirmed prediabetes, a BMI of ≥ 25 kg/m2 (≥ 23 kg/m2 for Asians), English proficiency, and smartphone users. This U.S. study is conducted at Johns Hopkins Medicine in Baltimore, MD, and Reading Hospital (Tower Health) in Reading, PA. DISCUSSION: Prediabetes is a significant public health issue, necessitating scalable interventions for the millions affected. Our pragmatic clinical trial is unique in directly comparing a fully automated AI-powered approach without direct human coach interaction. If proven effective, it could be a scalable, cost-effective strategy. This trial will offer vital insights into both AI and human coach-based behavioral change strategies in real-world clinical settings. TRIAL REGISTRATION: ClinicalTrials.gov NCT05056376. Registered on September 24, 2021, https://clinicaltrials.gov/study/NCT05056376.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Abusamaan MS, Ballreich J, Dobs A, et al. Effectiveness of artificial intelligence vs. human coaching in diabetes prevention: a study protocol for a randomized controlled trial. Trials. 2024. PMID: 38755706. doi:10.1186/s13063-024-08177-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。